Efficacy of an irreversible BTK inhibitor, Ibrutinib on allergen reactivity in patients suffering from B-cell malignancies
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- 23 Mar 2017 New trial record
- 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology